Blueprint Medicines SG&A Expense (TTM) Analysis

Blueprint Medicines Corp (BPMC)

116.40 +4.70 (+4.21%) USD | NASDAQ | Jul 08, 16:00

116.40 0.00 (0.00%) After-Hours: 17:47

SG&A Expense (TTM) Chart

Historical SG&A Expense (TTM) Data

View and export this data back to 2014. Upgrade now.

Date	Value
March 31, 2024	305.54M
December 31, 2023	292.94M
September 30, 2023	277.64M
June 30, 2023	264.51M
March 31, 2023	251.27M
December 31, 2022	237.37M
September 30, 2022	227.55M
June 30, 2022	219.75M
March 31, 2022	210.35M
December 31, 2021	195.29M
September 30, 2021	183.63M
June 30, 2021	171.20M
March 31, 2021	164.09M
December 31, 2020	157.74M
September 30, 2020	147.47M
June 30, 2020	135.74M
March 31, 2020	115.49M
December 31, 2019	96.39M
September 30, 2019	77.77M

Date	Value
June 30, 2019	64.16M
March 31, 2019	54.57M
December 31, 2018	47.93M
September 30, 2018	42.38M
June 30, 2018	37.71M
March 31, 2018	32.21M
December 31, 2017	27.99M
September 30, 2017	24.88M
June 30, 2017	22.40M
March 31, 2017	20.26M
December 31, 2016	19.22M
September 30, 2016	17.85M
June 30, 2016	17.18M
March 31, 2016	16.33M
December 31, 2015	14.46M
September 30, 2015	13.79M
June 30, 2015	11.49M
March 31, 2015	9.089M
December 31, 2014	7.891M

SG&A Expense Definition

SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.

Read full definition.

SG&A Expense (TTM) Range, Past 5 Years

77.77M

Minimum

Sep 2019

305.54M

Maximum

Mar 2024

196.41M

Average

195.29M

Median

Dec 2021

SG&A Expense (TTM) Benchmarks